​

Funding Round

Post-IPO Equity - Cullinan Therapeutics

Post-IPO Equity - Cullinan Therapeutics

Investment Firm

Overview

Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics used to end a drug program quickly.

Announced Date

Apr 16, 2024

Funding Type

Post Ipo Equity

Highlights

N/A

Location

N/A

Social

N/A

Investor Lead

N/A

Participant Investors

11

Investor Name
Participant InvestorBraidwell
Participant InvestorOrbiMed
Participant InvestorBlue Owl
Participant InvestorForesite Capital
Participant InvestorInvus

Round Details and Background

Cullinan Therapeutics raised $280000000 on 2024-04-16 in Post-IPO Equity

Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics used to end a drug program quickly.

Company Funding History

5

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Dec 17, 2020
Series C - Cullinan Therapeutics
15-131.2M
Mar 31, 2022
Post-IPO Equity - Cullinan Therapeutics
-10.0M
Apr 16, 2024
Post-IPO Equity - Cullinan Therapeutics
14-280.0M
Oct 03, 2017
Series A - Cullinan Therapeutics
5-150.0M

Recent Activity

There is no recent news or activity for this profile.